The aim of this study was to evaluate the efficacy and safety of CapeOX plus bevacizumab with a planned oxaliplatin stop-and-go strategy in Japanese patients with metastatic colorectal cancer (mCRC).
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2oG0kWj
via IFTTT
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
Δημοφιλείς αναρτήσεις
-
Cancer is associated with genomic instability and aging. Genomic instability stimulates tumorigenesis, whereas deregulation of oncogenes acc...
-
Eribulin is one of the newer chemotherapeutic agents approved for use in later line treatment of patients with metastatic breast cancer. Pha...
-
Abstract Helmet manufacturers recommend replacing a bicycle helmet after an impact or after anywhere from 2 to 10 years of use. The goal o...
-
Publication date: 10 June 2017 Source: Journal of Controlled Release, Volume 255 Author(s): Ožbej Zupančič, Andreas Bernkop-Schnürch Pept...
-
Publication date: 10 June 2017 Source: Journal of Controlled Release, Volume 255 Author(s): Chad S. Cummings, Katherine Fein, Hironobu Mur...
-
Caring for Patients with Physical Disabilities: Assessment of an Innovative Spinal Cord Injury Session that Addresses an Educational Gap Des...
-
<span class="paragraphSection"><div class="boxTitle">Abstract</div>It is not clear whether breast canc...
-
Abstract Varroa destructor is one of the scourges of global beekeeping. It was detected for the first time in Benin in 2011 on the honeyb...
-
Hydroxyurea (HU) has a long history of clinical and scientific use as an antiviral, antibacterial, and antitumor agent. It inhibits ribonucl...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου